Skip to main content
Cisen Pharmaceutical Co.,Ltd. logo

Cisen Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 603367 ISIN · CNE100002VG4 LEI · 836800T7RRJXURVHYS35 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,110 across all filing types
Latest filing 2024-08-27 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 603367

About Cisen Pharmaceutical Co.,Ltd.

https://www.cisen-pharma.com/

Cisen Pharmaceutical Co.,Ltd. is a comprehensive enterprise dedicated to the research, development, production, and marketing of a diverse range of medicinal products. The company specializes in the manufacture of large-volume injections, small-volume injections, and solid oral dosage forms, including tablets and capsules. Its product portfolio addresses critical therapeutic areas such as parenteral nutrition, anti-infectives, cardiovascular health, and anesthesia. Cisen Pharmaceutical maintains an integrated value chain, producing both active pharmaceutical ingredients (APIs) and finished formulations. The organization emphasizes technological innovation and stringent quality management systems to ensure the efficacy and safety of its medical solutions. By leveraging advanced manufacturing capabilities and a robust distribution network, the company provides essential healthcare products to clinical institutions and medical providers.

Recent filings

Filing Released Lang Actions
辰欣药业股份有限公司2024年半年度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled "2024 年半年度报告" which translates to "2024 Semi-Annual Report." It contains detailed financial data, management discussion and analysis, company information, financial indicators, and operational details for the period January 1, 2024 to June 30, 2024. The document is lengthy (15,000 characters) and includes actual financial statements and substantive financial data. It is not a brief announcement or a certification letter. The content matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and analysis. Therefore, the correct classification is IR with high confidence. H1 2024
2024-08-27 Chinese
辰欣药业股份有限公司第五届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the company's fifth board of directors' fourth meeting, including approvals of the 2024 semi-annual report, fundraising usage, stock incentive plans, capital changes, dividend arrangements, and scheduling of a shareholders' meeting. It references multiple related announcements and reports published separately on the Shanghai Stock Exchange website. The document itself is a formal board meeting resolution announcement, not the full semi-annual report or financial statements. It contains no substantive financial data or full report content but summarizes board decisions and approvals. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board decisions and management matters.
2024-08-27 Chinese
中泰证券股份有限公司关于辰欣药业股份有限公司募投项目结项并将节余募集资金及将部分募投项目剩余尾款永久补充流动资金的核查意见
Regulatory Filings
2024-08-27 Chinese
辰欣药业股份有限公司公司章程（2024年8月修订）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (公司章程) of 辰欣药业股份有限公司, revised in August 2024. It contains detailed provisions on company governance, shareholder rights, board structure, share issuance, shareholder meetings, voting procedures, and other corporate governance matters. It references relevant Chinese laws such as the Company Law and Securities Law, and includes detailed rules on shareholder meetings, board and management roles, share transfers, and capital changes. The content is a governance document outlining the internal rules and structure of the company rather than a financial report, earnings release, or announcement. It is not a report publication announcement or a brief notice but a comprehensive governance charter. Therefore, the document fits the category of Governance Information (CGR).
2024-08-27 Chinese
辰欣药业股份有限公司第五届董事会薪酬与考核委员会2024年第三次会议董事会薪酬与考核委员会意见
Remuneration Information Classification · 95% confidence The document is a formal opinion from the Board's Remuneration and Assessment Committee regarding the unlocking of restricted stock under a stock incentive plan. It discusses compliance with internal regulations and approval of stock release conditions. This content pertains to executive compensation and stock incentive matters, which aligns with Remuneration Information filings. The document is short and specific to compensation and stock awards, not a full report or announcement of voting results or management changes.
2024-08-27 Chinese
山东国曜琴岛（济南）律师事务所关于辰欣药业股份有限公司2020年限制性股票激励计划回购注销部分限制性股票和首次授予部分第三个解除限售期解除限售条件成就的法律意见书
Regulatory Filings
2024-08-27 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.